阑尾来源腹膜假黏液瘤完全减瘤联合HIPEC生存预测列线图的开发与验证
本研究基于单中心1994—2018年前瞻性收集的1102例阑尾来源腹膜假黏液瘤行完全减瘤术联合HIPEC的患者数据,随机分为开发集(70%)与验证集(30%),用Cox回归筛选预后因素并构建预测总生存和无病生存的列线图,列线图区分度与校准度良好。
要点
- 肿瘤标志物升高、腹膜癌指数、胃切除和肿瘤分级是无病生存的独立预测因素。
- 性别、年龄、肿瘤标志物升高、腹膜癌指数和肿瘤分级影响总生存。
- 列线图使用方便,可用于患者管理和临床试验设计。
核心结论
- 筛选出临床重要的独立生存与复发预测因素,构建了预测总生存和无病生存的列线图。
- 两个列线图使用方便,可用于患者管理和临床试验设计。
研究设计与样本
- 回顾性研究,使用单中心1994—2018年前瞻性收集的行减瘤术联合HIPEC的患者数据。
- 2637次减瘤术联合HIPEC操作中,1102例(41.8%)为阑尾来源腹膜假黏液瘤行完全减瘤术,女性占64.4%,中位年龄57.0岁(IQR 48.0-66.0)。
- 队列随机分为开发集(70%)和验证集(30%),采用Cox比例风险回归进行单因素和多因素分析。
- 用一致性指数(C指数)评价模型预后性能,通过比较预测与观察概率校准列线图。
主要发现
- 肿瘤标志物升高、腹膜癌指数、胃切除和肿瘤分级是无病生存的独立预测因素。
- 性别、年龄、肿瘤标志物升高、腹膜癌指数和肿瘤分级影响总生存。
- 列线图在预测生存方面表现良好。
- 队列中位总生存为16.5年(95%CI 13.7-19.2),5年生存概率为80.2%。
- 中位无病生存为10.3年(95%CI 7.2-13.3),5年无复发生存概率为60.5%。
临床怎么用
- 列线图可用于支持治疗策略制定和患者随访分层。
- 列线图使用方便,适用于患者管理和临床试验设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Pseudomyxoma peritoni, a rare condition characterized by mucinous ascites and peritoneal deposits, mainly originates from a ruptured mucinous appendix tumor and is considered an indolent disease but can progress and become fatal. Optimal treatment to improve cure and survival rates involves complete cytoreductive surgery (CCRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Accurate predictive models are useful in supporting and informing treatment strategies and stratifying patient follow-up. OBJECTIVE: To evaluate the prognostic significance of clinically important variables and generate validated nomograms to predict overall (OS) and disease-free survival (DFS) following CCRS and hyperthermic intraperitoneal HIPEC for pseudomyxoma peritonei (PMP) of appendiceal origin. DESIGN, SETTING, AND PARTICIPANTS: This retrospective study used prospectively collected data on patients who had cytoreductive surgery (CRS) and HIPEC in a single institution between 1994 and 2018. The cohort was randomly allocated into development (70%) and validation (30%) sets. Univariate and multivariate analyses were performed with Cox proportional hazards regression. MAIN OUTCOMES AND MEASURES: A prediction model was developed with significant prognostic factors identified by multivariate analysis. The model's prognostic performance was evaluated with the concordance index (C index). The nomogram was calibrated by comparing the predicted and observed probabilities. RESULTS: Of 2637 CRS and HIPEC operations, 1102 patients (female, 64.4%; median age [IQR], 57.0 [48.0-66.0] years) (41.8%) had CCRS for PMP of appendiceal origin. Elevated tumor markers, peritoneal carcinomatosis index, gastrectomy, and tumor grade were independent predictive factors for DFS. Gender, age, elevated tumor makers, peritoneal carcinomatosis index, and tumor grade influenced OS. The nomograms were generated with respective prognostic factors. The nomograms showed good performance in predicting survival. Median OS of the cohort was 16.5 years (95% CI, 13.7-19.2) with a 5-year probability of survival of 80.2%. The median DFS was 10.3 years (95% CI, 7.2- 13.3) and the 5-year probability of recurrence-free survival was 60.5%. CONCLUSIONS AND RELEVANCE: Clinically important independent predictors for survival and recurrence were selected to develop the nomograms for OS and DFS. These 2 nomograms are user friendly and useful tools for patient management with clinical trial design applications.
引用
- Chandrakumaran K, Carr NJ, Mohamed F, et al. Development and Validation of Nomograms to Predict Survival in Patients Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin. JAMA Surg. 2023. PMID: 36920381. doi:10.1001/jamasurg.2023.0112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。